Document is current

Article History

Received: 10 December 2019

Accepted: 6 April 2020

First Online: 2 June 2020

Duality of interest

: JAS has received a grant in support of an investigator-initiated trial from AstraZeneca. FZ has acted as a speaker for Napp Pharmaceuticals. DRW has received honoraria as a speaker for AstraZeneca, Sanofi-Aventis and Lilly and has received research funding support from Novo Nordisk. VRA has served as a consultant for Adocia, AstraZeneca, BD, Novo Nordisk, Sanofi and Zafgen, with clinical trials/research support to employer institution from AstraZeneca/BMS, Boehringer Ingelheim, Calibra, Eisai, Fractyl, Janssen, Novo Nordisk, Sanofi and Theracos. Her spouse is an employee of Merck Research Laboratories. KK has received honoraria from Abbot, AstraZeneca, Berlin-Chemie AG/Menarini Group, Boehringer Ingelheim, Eli Lilly, Janssen, MSD, Novartis, Novo Nordisk, Roche and Sanofi, and research support from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, MSD, Novartis, Novo Nordisk, Roche and Sanofi. MJD has acted as a consultant, advisory board member and speaker for Novo Nordisk, Sanofi-Aventis, Lilly, MSD, Boehringer Ingelheim, AstraZeneca and Janssen, an advisory board member for Servier and a speaker for Mitsubishi Tanabe Pharma Corporation and Takeda Pharmaceuticals International Inc. She has received grants in support of investigator and investigator-initiated trials from Novo Nordisk, Sanofi-Aventis, Lilly, Boehringer Ingelheim, Janssen and AstraZeneca. EMB, FT and EWG report no conflicts of interest.